EP0572644A1 - 9-(Beta-D-Xylofuranozyl)adenin und 1-(Beta-D-Xylofuranozyl)-Cytozinderivate, ihre Herstellung und ihre therapeutische Verwendung - Google Patents

9-(Beta-D-Xylofuranozyl)adenin und 1-(Beta-D-Xylofuranozyl)-Cytozinderivate, ihre Herstellung und ihre therapeutische Verwendung

Info

Publication number
EP0572644A1
EP0572644A1 EP93902329A EP93902329A EP0572644A1 EP 0572644 A1 EP0572644 A1 EP 0572644A1 EP 93902329 A EP93902329 A EP 93902329A EP 93902329 A EP93902329 A EP 93902329A EP 0572644 A1 EP0572644 A1 EP 0572644A1
Authority
EP
European Patent Office
Prior art keywords
adenine
group
xylofurannosyl
acetyl
cytosine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93902329A
Other languages
English (en)
French (fr)
Inventor
Jean-Louis Imbach
Gilles Résidence Barque-des-Arceaux GOSSELIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Publication of EP0572644A1 publication Critical patent/EP0572644A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Definitions

  • R 2 represents a hydrogen atom, a (C 2-4 ) alkanoyl group, an aroyl group or a nitro group,
  • R 3 represents a hydrogen atom, a (C 2-4 ) alkanoyl group, an aroyl group or a nitro group,
  • R 1 , R 2 and R 3 represent an NO 2 group are prepared from the corresponding compounds in which R 1 , R 2 and R 3 represent a hydrogen atom by reaction with nitric acid in the presence acetic anhydride and urea.
  • the compounds of the invention have been subjected to a series of pharmacological tests which have demonstrated their advantage as substances with therapeutic activities.
  • the percentage of protection of infected cells by treatment with the compounds is calculated by applying the formula proposed by Pauwels et al.
  • the compounds of the invention can therefore be used for their antiproliferative and herpetic activity and in the topical treatment of skin infections with HSV1 and HSV2.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
EP93902329A 1991-12-12 1992-12-14 9-(Beta-D-Xylofuranozyl)adenin und 1-(Beta-D-Xylofuranozyl)-Cytozinderivate, ihre Herstellung und ihre therapeutische Verwendung Withdrawn EP0572644A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9115420A FR2684997A1 (fr) 1991-12-12 1991-12-12 Derives de la 9-(beta-d-xylofurannosyl) adenine et de la 1-(beta-d-xylofurannosyl) cytosine, leur preparation et leur application en therapeutique.
FR9115420 1991-12-12

Publications (1)

Publication Number Publication Date
EP0572644A1 true EP0572644A1 (de) 1993-12-08

Family

ID=9419960

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93902329A Withdrawn EP0572644A1 (de) 1991-12-12 1992-12-14 9-(Beta-D-Xylofuranozyl)adenin und 1-(Beta-D-Xylofuranozyl)-Cytozinderivate, ihre Herstellung und ihre therapeutische Verwendung

Country Status (5)

Country Link
EP (1) EP0572644A1 (de)
JP (1) JPH06505510A (de)
CA (1) CA2103884A1 (de)
FR (1) FR2684997A1 (de)
WO (1) WO1993012128A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06321784A (ja) * 1993-03-18 1994-11-22 Nippon Chemiphar Co Ltd 抗ヒト免疫不全ウイルス剤
US20020120130A1 (en) 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
JPH09504785A (ja) * 1993-09-10 1997-05-13 エモリー、ユニバーシティー 抗ｂ型肝炎ウイルス活性を有するヌクレオシド
CA2171518A1 (en) * 1995-03-24 1996-09-25 Douglas Patton Kjell Process for the preparation of 2,2'-anhydro- and 2' -keto-1-(3', 5'-di-o-protected-.beta.-d-arabinofuranosyl) nucleosides
EP1655033A1 (de) 1995-06-07 2006-05-10 Emory University Nucleoside mit anti-hepatitis B virus Wirksamkeit
DE10110355A1 (de) 2001-03-03 2002-09-12 Ulrich Walker Bekämpfung von Nebenwirkungen
SG10201913554YA (en) 2011-12-22 2020-03-30 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR6164M (de) * 1966-10-13 1968-07-08
DE2105560A1 (de) * 1971-02-06 1972-09-07 Boehringer Mannheim Gmbh, 6800 Mannheim Purinribonucleosid-Derivate und Verfahren zur Herstellung derselben
FR2528311B1 (fr) * 1982-06-14 1985-06-14 Synthelabo Compositions pharmaceutiques a base de xylosides et lyxosides de bases puriques et pyrimidiques
DK524588A (da) * 1987-09-22 1989-03-23 Warner Lambert Co Middel til behandling af aids
SE8704298D0 (sv) * 1987-11-03 1987-11-03 Astra Ab Compounds for use in therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9312128A1 *

Also Published As

Publication number Publication date
CA2103884A1 (fr) 1993-06-13
FR2684997A1 (fr) 1993-06-18
WO1993012128A1 (fr) 1993-06-24
JPH06505510A (ja) 1994-06-23

Similar Documents

Publication Publication Date Title
JP2728148B2 (ja) アミノアルギニンの分離および身体内の酸化窒素生成を遮断するための用途
KR920006365A (ko) 신규의 프레그나-1,4-디엔 -3,20-디온-16,17-아세탈-21-에스테르류, 이것의 제조방법, 이것을 함유한 조성물 및 염증질환의 치료방법
JPH03236318A (ja) 抗うつ剤
WO1993012128A1 (fr) DERIVES DE LA 9-(β-D-XYLOFURANNOSYL) ADENINE ET DE LA 1-(β-D-XYLOFURANNOSYL)CYTOSINE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
Baker et al. Prodrugs of 9-(. beta.-D-arabinofuranosyl) adenine. 2. Synthesis and evaluation of a number of 2', 3'-and 3', 5'-di-O-acyl derivatives
JPH02229199A (ja) 神経科用の合成の両親媒性複合糖質
EP0098186A1 (de) Purin- oder Pyrimidinxyloside und -lyxoside enthaltende pharmazeutische Zusammensetzungen
EP0080819A1 (de) 11-0-Alkylerythromycin A Derivate
JPH04202127A (ja) インターロイキン―１産生抑制剤
EP0233105B1 (de) Therapeutische Zusammenstellungen auf Basis von 3-Alkoxyflavonen und Derivate von 3-Alkoxyflavonen
US4954485A (en) 2',3'-dideoxy-4-thio-uridine derivatives, process for their preparation and antivirus agents using them
DE69008085T2 (de) Oxetanocinderivate, ihre Salze und ihre Verwendung.
EP0772630B1 (de) Streptograminderivate, ihre herstellung und sie enthaltende pharmazeutische zubereitungen
EP0123605B1 (de) N-Cyclopropylmethyl-2-oxo-3-diparamethoxyphenyl-5,6-triazin, Verfahren zu seiner Herstellung und seine Verwendung als Arzneimittel
EP0121635A1 (de) 3',5'-Diarabinoside, Verfahren zu ihrer Herstellung und ihre therapeutische Verwendung
STEARNS et al. 3, 6-Di-O-methyl-D-galactosamine Hydrochloride (2-Amino-2-deoxy-3, 6-di-O-methyl-D-galactose Hydrochloride)
RU2024546C1 (ru) ГЛИКОПЕПТИД β-ГЛИЦИРРИЗИНОВОЙ КИСЛОТЫ С ДИБУТИЛОВЫМ ЭФИРОМ L-ГЛУТАМИНОВОЙ КИСЛОТЫ, ПРОЯВЛЯЮЩИЙ АНТИ-СПИД-АКТИВНОСТЬ
Rooney et al. Synthesis of sulfonylhydrazine derivatives with monoamine oxidase inhibitory activity
JPS6054960B2 (ja) 抗しゆよう性セプタシジン類似体
US4126616A (en) N-propylnorapomorphine diesters
JPH04501867A (ja) 抗ウィルス剤としての５´―アルキルホスホニルヌクレオシド
US4939156A (en) New tetramethyl-cis-diaza-bicyclo{4.2.0}octane-3,5-dione derivatives having differentiation-inducing activity and antiviral activity
EP0003090A2 (de) 17 Alpha-aryle oder 17 Alpha-heteroaryle Steroide, Verfahren zu ihrer Herstellung, ihre Verwendung als Arzneimittel und diese enthaltende pharmazeutische Zubereitungen
US4906620A (en) Medicament comprising as active ingredient N6 substituted adenosine
JPH07285877A (ja) Ｈｉｖ−１の逆転写酵素阻害剤

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17P Request for examination filed

Effective date: 19931206

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19950701